The U.S. Food and Drug Administration has approved dasiglucagon (ZEGALOGUE) from Novo Nordisk for the emergency treatment of severe hypoglycemia caused by insulin treatment, creating an important alternative to glucagon to enhance accessibility for patients. This approval positions Novo Nordisk to expand its glycemic management portfolio by offering a longer-acting and more stable formulation that could disrupt the traditional emergency response market dominated by Eli Lilly and others.